Use of aripiprazole in tardive dyskinesia: An open label study of six cases

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 416-419

  Rajarethinam, Rajaprabhakaran ^a   Dziuba, John ^a   Manji, Suzanne ^a   Pizzuti, Albert ^a   Lachover, Leonard ^a   Keshavan, Matcheri ^a,b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antipsychotics; EPS; Schizoaffective disorder; Schizophrenia; Tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; DRUG DERIVATIVE; FLUPHENAZINE; FLUPHENAZINE DEPOT; HALOPERIDOL; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSKINESIA; FEMALE; HUMAN; MALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; CASE REPORT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUPHENAZINE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 77449120779     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970902995612     Document Type: Article

References (16)

1. Abbasian C, Power P. 2009. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol Mar;23(2):214-215 Epub 2008 May 30.
2. Casey D. 1999. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35(Suppl):S61-66.
3. Casey D. 2004. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25-28.
4. Correll C, Schenk E. 2008. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21(2):151-156.
5. Duggal H, Mendhekar D. 2006. Atypical antipsychotics, tardive dyskinesia, and D(2) receptors. Am J Psychiatry 163(8): 1449-1450.
6. Fleischhacker W, Lemmens P, van Baelen B. 2001. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Pharmacopsychiatry 34(3):104-110.
7. Kane JM. 2004. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65(Suppl 9):16-20.
8. Kantrowitz JT, Srihari V, Tek. 2007. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 27(5):525-526.
9. Lim HK, Pae CU, Lee C, Lee. 2008. Tardive dystonic symptoms associated with aripiprazole treatment. Prog Neuropsychophar-macol Biol Psychiatry 32(2):589-590.
10. Lykouras L, Rizos E, Gournellis R. 2007. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 31(7):1535-1536.
11. Miller del D, Eudicone JM, Pikalov A, Kim. 2007. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 68(12):1901-1906.
12. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39(4):486-487
13. Sharma A, Ramaswamy S, Dewan VK. 2005. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 7(1):36.
14. Soares-Weiser K, Fernandez HH. 2007. Tardive dyskinesia. Semin Neurol 27(2):159-169.
15. Tandon R, Jibson MD. 2001. Pharmacologic treatment of schizophrenia: what the future holds. CNS Spectr 6(12): 980-984, 986.
16. Tarsy D, Baldessarini RJ. 2006. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21(5):589-598.